Advertisements
Feeds:
Posts
Comments

Archive for the ‘Frontiers in Cardiology and Cardiovascular Disorders’ Category


In Europe, BigData@Heart aim to improve patient outcomes and reduce societal burden of atrial fibrillation (AF), heart failure (HF) and acute coronary syndrome (ACS).

Reporter: Aviva Lev-Ari, PhD, RN

 

PRESS RELEASE

The objective of BigData@Heart is to develop a data-driven translational research platform of unparalleled scale and phenotypical resolution, with the aim to improve patient outcomes and reduce societal burden of atrial fibrillation (AF), heart failure (HF) and acute coronary syndrome (ACS).

AF, HF and ACS are major drivers of cardiovascular disease (CVD), which causes more than 3.9 million deaths each year across Europe – accounting for 45% of all deaths (49% of deaths among women and 40% of deaths among men) – with 1.3 million of these deaths occuring before the age of 75 years. Of the total cost of CVD in the EU (€210 billion a year), around 53% (€111 billion) is due to health care costs, 26% (€54 billion) to productivity losses and 21% (€45 billion) to the informal care of people with CVD.(i)

Currently, the management of AF, HF and ACS is complicated by their complex aetiology and heterogeneous prognoses. This renders the response to therapy unpredictable, with large variations amongst individuals and, importantly, small or undetectable treatment effects in large patient trials. Also, tolerability of medications and adherence to current treatments shows wide variations. Aside from the medical need, drug development pipelines from early target validation through to late post-marketing work have proven to be slow and high-risk. The lack of high-resolution biomarkers and computable definitions frustrates progress in the development of successful CVD therapies. There is a clear need for a better definition of CVD through improved biomarkers and endpoints, as well as its outcomes and prognoses.

BigData@Heart uniquely brings together key players and stakeholders in the CVD field to address these challenges. The clinical researchers involved have been instrumental in shaping current AF, HF and ACS treatment and management in Europe. They will join forces with leading epidemiologists, big data scientists, leading cardiovascular practitioners, pharmaceutical industry scientists, experts in ethics and legal aspects, and patient organisations from across Europe. The BigData@Heart consortium will develop a data-driven translational research platform which will be aiming at delivering clinically relevant disease phenotypes, scalable insights from real-world evidence, best-practices in drug development, and personalised medicines through advanced analytics.

For the first time, BigData@Heart will assemble European-wide consented cohorts (conventional research data), electronic health records (EHRs) in population settings (e.g. CALIBER, ABUCASIS, MONDRIAAN), hospital based EHRs, disease quality improvement registries (e.g. SWEDEHEART, NICOR, SwedeHF), clinically recorded imaging data, and trial data (covering over 75,000 patients).

BigData@Heart will deliver population relevant disease-based datasets (with > 5 million cases of HF, AF and ACS and healthy population cohorts > 16 million people accruing a further > 500,000 cases on follow up) and phenotypic depth with biomarker, behavioural, clinical, imaging data and genomic information with genome-wide association study (GWAS) consortia in each disease (AFGen, HERMES, GENIUS-CHD).

 

This project will develop and test a framework that will enable big data driven cardiovascular research, including the development of:

  • New definitions of diseases and outcomes that are universal, computable, and relevant for patients, clinicians, industry and regulators.
  • Informatics platforms that link, visualise and harmonise data sources of varying types, completeness and structure.
  • Data science techniques to develop new definitions of disease, identify new phenotypes, and construct personalized predictive models.
  • Guidelines that allow for cross-border usage of big data sources acknowledging ethical and legal constraints as well as data security.

The ultimate expected impact of BigData@Heart on science, industry, policies, and patients includes a better understanding of heart disease, the development of new therapy targets, improved drug and device development/utilisation, and laying a scientific foundation for progress in the personalised treatment and management of CVD.

 

BigData@Heart is a 5-year, € 19 million project supported by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European pharmaceutical industry.  The pharmaceutical industry contributes half of BigData@Heart’s budget, while the other half is funded by the European Commission.

 

BigData@Heart Structure and Participants

The consortium is being jointly led by Prof. Diederick E. (Rick) Grobbee from the University Medical Center Utrecht (UMCU) and Dr. Gunnar Brobert from Bayer and consists of 19 partners coming from academia, medical associations, pharmaceutical industry, SMEs and patient organisations:

  • University Medical Center Utrecht (UMCU)
  • Charité – Universitätsmedizin Berlin (Charité)
  • European Society of Cardiology (ESC)
  • European Heart Network (EHN)
  • University College London (UCL)
  • University of Cambridge (CAM)
  • International Consortium for Health Outcomes Measurement (ICHOM)
  • Fundación para la investigación del Hospital Clinico de la Comunidad Valenciana (INCLIVA)

‘BigData@Heart will show how big data can drive progress in the treatment and management of CVD’, Prof. Diederick E. (Rick) Grobbee, University Medical Center Utrecht (UMCU)

 

For more info: www.bigdata-heart.eu

SOURCE

From: IMI BigDataAtHeart <info=vitaltransformation.com@mail231.atl171.mcdlv.net> on behalf of IMI BigDataAtHeart <info@vitaltransformation.com>

Reply-To: <us15-13fc61bdf7-d3376746c8@conversation01.mailchimpapp.com>

Date: Monday, July 10, 2017 at 6:05 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Press Release: Big Data for Better Hearts: Breaking new ground for millions of patients with heart disease in Europe

Advertisements

Read Full Post »


SNP-based Study on high BMI exposure confirms CVD and DM Risks – no associations with Stroke

Reporter: Aviva Lev-Ari, PhD, RN

Genes Affirm: High BMI Carries Weighty Heart, Diabetes Risk – Mendelian randomization study adds to ‘burgeoning evidence’

by Crystal Phend, Senior Associate Editor, MedPage Today, July 05, 2017

 

The “genetically instrumented” measure of high BMI exposure — calculated based on 93 single-nucleotide polymorphisms associated with BMI in prior genome-wide association studies — was associated with the following risks (odds ratios given per standard deviation higher BMI):

  • Hypertension (OR 1.64, 95% CI 1.48-1.83)
  • Coronary heart disease (CHD; OR 1.35, 95% CI 1.09-1.69)
  • Type 2 diabetes (OR 2.53, 95% CI 2.04-3.13)
  • Systolic blood pressure (β 1.65 mm Hg, 95% CI 0.78-2.52 mm Hg)
  • Diastolic blood pressure (β 1.37 mm Hg, 95% CI 0.88-1.85 mm Hg)

However, there were no associations with stroke, Donald Lyall, PhD, of the University of Glasgow, and colleagues reported online in JAMA Cardiology.

The associations independent of age, sex, Townsend deprivation scores, alcohol intake, and smoking history were found in baseline data from 119,859 participants in the population-based U.K. Biobank who had complete medical, sociodemographic, and genetic data.

“The main advantage of an MR approach is that certain types of study bias can be minimized,” the team noted. “Because DNA is stable and randomly inherited, which helps to mitigate errors from reverse causality and confounding, genetic variation can be used as a proxy for lifetime BMI to overcome limitations such as reverse causality and confounding, a process that hampers observational analyses of obesity and its consequences.”

 

Other related articles published in this Open Access Online Scientific Journal include the following:

9 results for Kindle Store : “Aviva Lev-Ari”

Sort by 
Relevance
Featured
Price: Low to High
Price: High to Low
Avg. Customer Review
Publication Date
  • Product Details

    Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

    Nov 28, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

    Jun 20, 2013 | Kindle eBook

    by Margaret Baker PhD and Tilda Barliya PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

    May 13, 2017 | Kindle eBook

    by Larry H. Bernstein and Demet Sag
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

    Jul 21, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Prabodah Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

    Dec 26, 2015 | Kindle eBook

    by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

    Nov 22, 2015 | Kindle eBook

    by Sudipta Saha PhD and Ritu Saxena PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

    Aug 10, 2015 | Kindle eBook

    by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

    Dec 26, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

    Nov 29, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly

 

Read Full Post »


Arrhythmias Detection: Speeding Diagnosis and Treatment – New deep learning algorithm can diagnose 14 types of heart rhythm defects by sifting through hours of ECG data generated by some REMOTELY iRhythm’s wearable monitors

Reporter: Aviva Lev-Ari, PhD, RN

 

Long term, the group hopes this algorithm could be a step toward expert-level arrhythmia diagnosis for people who don’t have access to a cardiologist, as in many parts of the developing world and in other rural areas. More immediately, the algorithm could be part of a wearable device that at-risk people keep on at all times that would alert emergency services to potentially deadly heartbeat irregularities as they’re happening.

said Pranav Rajpurkar, a graduate student and co-lead author of the paper. “For example, two forms of the arrhythmia known as second-degree atrioventricular block look very similar, but one requires no treatment while the other requires immediate attention.”

To test accuracy of the algorithm, the researchers gave a group of three expert cardiologists 300 undiagnosed clips and asked them to reach a consensus about any arrhythmias present in the recordings. Working with these annotated clips, the algorithm could then predict how those cardiologists would label every second of other ECGs with which it was presented, in essence, giving a diagnosis.

http://news.stanford.edu/2017/07/06/algorithm-diagnoses-heart-arrhythmias-cardiologist-level-accuracy/

 iRhythm, maker of portable ECG devices

Image Source:

https://www-technologyreview-com.cdn.ampproject.org/c/s/www.technologyreview.com/s/608234/the-machines-are-getting-ready-to-play-doctor/amp/

Cardiologist-Level Arrhythmia Detection with Convolutional Neural Networks

We develop an algorithm which exceeds the performance of board certified cardiologists in detecting a wide range of heart arrhythmias from electrocardiograms recorded with a single-lead wearable monitor. We build a dataset with more than 500 times the number of unique patients than previously studied corpora. On this dataset, we train a 34-layer convolutional neural network which maps a sequence of ECG samples to a sequence of rhythm classes. Committees of board-certified cardiologists annotate a gold standard test set on which we compare the performance of our model to that of 6 other individual cardiologists. We exceed the average cardiologist performance in both recall (sensitivity) and precision (positive predictive value).

Subjects: Computer Vision and Pattern Recognition (cs.CV)
Cite as: arXiv:1707.01836 [cs.CV]
(or arXiv:1707.01836v1 [cs.CV] for this version)

Submission history

From: Awni Hannun [view email]
[v1] Thu, 6 Jul 2017 15:42:46 GMT (852kb,D)

SOURCE

Active Learning Applied to Patient-Adaptive Heartbeat Classification

Part of: Advances in Neural Information Processing Systems 23 (NIPS 2010)

[PDF] [BibTeX] [Supplemental]

Authors

Abstract

While clinicians can accurately identify different types of heartbeats in electrocardiograms (ECGs) from different patients, researchers have had limited success in applying supervised machine learning to the same task. The problem is made challenging by the variety of tasks, inter- and intra-patient differences, an often severe class imbalance, and the high cost of getting cardiologists to label data for individual patients. We address these difficulties using active learning to perform patient-adaptive and task-adaptive heartbeat classification. When tested on a benchmark database of cardiologist annotated ECG recordings, our method had considerably better performance than other recently proposed methods on the two primary classification tasks recommended by the Association for the Advancement of Medical Instrumentation. Additionally, our method required over 90% less patient-specific training data than the methods to which we compared it.

SOURCE

Cardiologist-Level Arrhythmia Detection With Convolutional Neural Networks

Pranav Rajpurkar*, Awni Hannun*, Masoumeh Haghpanahi, Codie Bourn, and Andrew Ng

A collaboration between Stanford University and iRhythm Technologies

https://stanfordmlgroup.github.io/projects/ecg/

JULY 6, 2017

Stanford computer scientists develop an algorithm that diagnoses heart arrhythmias with cardiologist-level accuracy

A new deep learning algorithm can diagnose 14 types of heart rhythm defects, called arrhythmias, better than cardiologists. This could speed diagnosis and improve treatment for people in rural locations.

The Machines Are Getting Ready to Play Doctor

An algorithm that spots heart arrhythmia shows how AI will revolutionize medicine—but patients must trust machines with their lives.

by Will Knight,  July 7, 2017

https://www-technologyreview-com.cdn.ampproject.org/c/s/www.technologyreview.com/s/608234/the-machines-are-getting-ready-to-play-doctor/amp/

The Dark Secret at the Heart of AI

No one really knows how the most advanced algorithms do what they do. That could be a problem.

by Will Knight, April 11, 2017

https://www.technologyreview.com/s/604087/the-dark-secret-at-the-heart-of-ai/

 

Read Full Post »


What is the history of STEMI? What is the current treatment for Cardiogenic Shock? The Case Study of Detroit Cardiogenic Shock Initiative

Reporter: Aviva Lev-Ari, PhD, RN

 

We present here five videos by Dr. William O’Neill, MD, Medical Director, Center for Structural Heart Disease at Henry Ford Health System, Detroit, MI.

Part 1 to Part 5 cover all aspects of clinical treatment for Cardiogenic Shock as the most advance stage of an Acute MI.

Dr. O’Neill presents a Treatment Model for Cardiogenic Shock that has the potential to be scaled up from a Regional Level in Detroit, MI to a National level including scaling up the Platform for Clinical Trials and Clinical Protocols for improving outcomes.

 

WATCH VIDEO – 

Part 1: History of STEMI

http://mindsofmedicineinaction.henryford.com/videos/detroit-cardiogenic-shock-initiative-part-1-history-of-stemi?utm_source=social&utm_medium=facebook&utm_content=cardiogenic_shock&utm_campaign=hef_7965

WATCH VIDEO

Part 2: New Protocol

http://mindsofmedicineinaction.henryford.com/videos/detroit-cardiogenic-shock-initiative-part-2-new-protocol

WATCH VIDEO

Part 3: Hospitals Joining

http://mindsofmedicineinaction.henryford.com/videos/detroit-cardiogenic-shock-initiative-part-3-hospitals-joining

WATCH VIDEO

Part 4: Collaboration, Results and Next Steps

http://mindsofmedicineinaction.henryford.com/videos/detroit-cardiogenic-shock-initiative-part-4-collaboration-results-and-next-steps

WATCH VIDEO

Part 5: Establishing Regional Programs

http://mindsofmedicineinaction.henryford.com/videos/detroit-cardiogenic-shock-initiative-part-5-establishing-regional-programs

Read Full Post »


Tweets by @pharma_BI and @AVIVA1950 at World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

Curator: Aviva Lev-Ari, PhD, RN

 

@pharma_BI

@AVIVA1950

 

All 57 RETWEETS by  World Forum from LPBI’s Twitter.com handles

@pharma_BI

@AVIVA1950

 

https://twitter.com/PartnersWMIF

  

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 @AVIVA1950 Medical Devices – Prevention methods, Big data , AI, Heart Failure a role for Government like “CVD Moonshot”

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI @AVIVA1950 #WMIF17 a working artificial heart is more needed than another stent, personalized sensors (diagnostics) reimbursment

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@pharma_BI @AVIVA1950 #WMIF17 Monetizing Diagnostics is key no reimbursement for regenerative medicine, biological system vs physical system

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Bruce Rosengard: Crowd sourcing future mechanism for funding innovations vs ROI funding, Partnerships Academia/Industry

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@pharma_BI @AVIVA1950 #WMIF17 E. Edelman: Ideas start in Academia, Residential teaching is eroding, Industry needs assuming role of Academia

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Ronald Tompkins, MD: Regulatory FDA/Bureaucracy needs be non-adversarial relations with Hospitals or Academia or industry

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI @AVIVA1950 #WMIF17 Timothy Ring, CEO, Bard: corporate controlled fund for acquisions rely on Start up community for acquisitions

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI, #WMIF17 Michael Mussallem CEO, Edwards Lifesciences Selling services – heart-lung machine: Perfusion is a product and Service

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Lewis Sandy, MD UnitedHealth 30% of care cost is WASTE, eliminate!! Collaborations Pharma Devices: Data Analytics KEY

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 @AVIVA1950 Jagmeet Singh, MGH Genetic profiling for early detection, Going upstream for the Genetics and the Prevention

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Omar Ishrak, PhD CEO, Medtronic Innovations are the essence of Medical Devices development as mission in technology

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Omar Ishrak, CEO, Medtronic Training Challenge Surgical Robotic patient comfort of minimal invasive therapy, cost lower

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Omar Ishrak, CEO, Medtronic Mitral Valve – platform for new generation of diagnostics ETERNAL: recover fast outcome

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Marc Semigran Myokardia Preclinical trials for early insights for Younger patient with cardiomiopaty and older patient

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 Makoto Suematsu initiative on Dementia, cases of +100 y-o without functional decline in Japan

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 @AVIVA1950 Makoto Suematsu, collaboration with NIH, Beyond the Border Masanori Aikawa AGING disease indication is novel

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 Innovations from Japan leveraged in a global corporation, Bayer, Academia and Industry Partnership investment from Bayer

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 @AVIVA1950 Makoto Suematsu, Pharma’s difficulty to data access the clinical data from Academic Hospitals, gov’t IT invest

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 Carsten Brunn, Bayer Osaka Innovation Center to facilitate Translational results transfer to Pharma, stem cell initiative

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI @AVIVA1950 #WMIF17 Hiroyuki Kawabata rate of CVD and HTN increased in Japan with aging population, national goal decrease BP

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI @AVIVA1950 #WMIF17 Benjamin Scirica, FDA requires PRAGMATIC TRIAL DESIGN, IDENTIFY DIFFERENT POPULATION FOR EXISTING DRUGS,

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 Rowe of Edwards Mitral Valve Trans catheter is the direction PATIENT ACCESS – who will benefit devices Improve Patient

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Cost of failure for AD at Eli Lilly, reduce failure rate, hedge bets to cut losses, investment may be deadend

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Offset AD prevent vs delay age of onsett is desirable, Pharma spend $70Billion on R&D, most is D NIH is R

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @pharma_BI, @AVIVA1950, Increase Research at Eli Lilly CEO, medicine will bring value, can’t apologies for drug failure, best time

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Stanley Shaw, MD, PhD Realization by physicians that monitoring Patients @Home is a TIME SAVER – tech adopted

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @pharma_BI Stanley Shaw Trusted Sources for Sharing genetic information with Academic Centers: Verily, AstraZeneca, AHA partnership

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @pharma_BI @AVIVA1950 Jonathan Rennert: histories of ECG before cardiac arrest: instruct do not drive, do not be alone at home

1 retweet

Retweet

1

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @pharma_Bi @AVIVA1950 Joe Kvedar, MD Implement technology for quality care, access and lower cost monitoring Patients while @Home

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Robert Bradway CEO, Amgen Value of innovation at a price that allows access and lowering cost of care

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Robert Bradway CEO, Amgen Cardiologist prescribed the medication for himself 6 month for insurance approval

0 replies1 retweet0 likes

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Norman Stockbridge, MD, PhD Director, Division of CV and Renal Products, FDA: Preserve randomization is key

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Elisabeth Björk, AstraZeneca asked Norman Stockbridge, FDA – pragmatic design avoid missing data is 12%

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Scott Wasserman, Amgen, AI will become part of Clinical Trial Design for investigational therapies and others

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Dean Li, Merck, Arrhythmia: Mutation if down played causes Arrhythmia if Overexpressed causes Arrhythmia

0 replies1 retweet0 likes

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Sean Harper, MD, Amgen in CVD complex traits phynotype more determinative then genotyping vs Oncology,

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Sean Harper, MD, Amgen Sean Harper, MD Investors:to Biotech – works on Oncology and on Orphan drugs

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Jean-François Formela, MD Coolest technology: CRISPR one injection reduction of effects in a genetic disease

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Highlights – LIVE Day 2: World Medical Innovation Forum – https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  16h16 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Ecosystem: Products, Patient Advocacy Groups and Regulators –alignment interaction among agencies: NIH, FDA

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  16h16 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Investment in Devices looks better vs CVD Drugs, Biologics are different, Nurtaceuticals some are harmful

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  16h16 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Robert Califf, Precision Medicine is over inflated except in Oncology, “in CVD, I wish to hear from you”

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  15h15 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Jessica Mega CMO Verily, Real Time monitoring, each Patient has own Portal, monitoring takes major resources

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  15h15 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Michael Mahoney: Challenges in Emerging Markets: China more regulation India – price very low expensive stent

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  15h15 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Microelectronics new direction: Endoscopy GI Pulmonary,SPINAL CORD STIMULATION: GU GI (Crohn),Neuromodulation

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Aarif Khakoo, MD Amgen 1,500,000 stroke Genetics will bring the breakthrough to atherosclerosis

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Craig Sponseller, Is triglycerides the right focus, Macrophage activation to prevent pathways resistance

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Aarif Khakoo, MD Amgen Cost is related to FAIL less – target selection is cardinal

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Clive Meanwell, Phase III needs different questions and more Phase IV needed

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Campbell Rogers, MD Clinical burden remains: Value for Patient economic value of the outcome of the

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Campbell Rogers, MD Imaging Efficiency free cost Plaque composition Coronary CT flow implication of stenosis

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Craig Sponseller, MD Pragmatic Clinical Trial Design: Novel Targets, collaboration of Academia and Industry

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  13h13 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons Reinvent Longitudinal Cohort Studies & Genomics sequencing – Concepts of Data Commons Analytics

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  13h13 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons 20% investigators take up 50% of the grants squeezing out the bandwidth need younger generation

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  13h13 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons, MD Pragmatic optimist in this position, scientists innovate for Patients would do it again

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  11h11 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  11h11 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Disruptive Dozen 1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

 

Compilation of Tweets on

@pharma_BI

and

@AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA19503h3 hours ago

 

@pharma_BI @AVIVA1950 #WMIF17 Disruptive Dozen 2. Harnessing Big Data and Deep Learning for Clinical Decision Support

1 retweet2 likes

  1. You Retweeted

@pharma_BI‏ @Pharma_BI  3h3 hours ago

 

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

1 retweet1 like

 

  1. Aviva Lev-Ari‏ @AVIVA19503h3 hours ago

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA •… https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

 

Aviva Lev-Ari‏ @AVIVA1950  22h22 hours ago

 

Highlights – LIVE Day 2: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA… https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

View Tweet activity

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF17 @Pharma_BI @AVIVA Frans van Houten CEO, Philips eICU -measure evolution to forcast 6 hours a deterioration reduction 40% of death

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF @pharma_BI @AVIVA1950 Robert Bradway Future at Amgen: Coming drug is Pharmcogenetics for atherosclerosis

LikeAviva Lev-Ari‏ @AVIVA1950  May 2

 

Robert Bradway CEO, Amgen Pay for benefit, for outcome, no pay if med does not do what it was supposed to do – REFUND patients poor outcome

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF17 @Pharma_BI @AVIVA1950 Robert Bradway CEO, Amgen Cardiologist prescribed the medication for himself 6 month for insurance approval

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF17 @Pharma_BI @AVIVA1950 Robert Bradway CEO, Amgen Value of innovation at a price that allows access and lowering cost of care

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF17 @pharma_Bi @AVIVA1950 Joe Kvedar, MD Implement technology for quality care, access and lower cost monitoring Patients while @Home

1 retweet

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

More

#WMIF17 @pharma_BI @AVIVA1950 Jonathan Rennert: histories of ECG before cardiac arrest: instruct do not drive, do not be alone at home

 

  1. Aviva Lev-Ari‏ @AVIVA1950 May 2

 

#WMIF17 @pharma_BI Stanley Shaw Trusted Sources for Sharing genetic information with Academic Centers: Verily, AstraZeneca, AHA partnership

View Tweet activity

  1. Aviva Lev-Ari‏ @AVIVA1950 May 2

 

#WMIF17 @Pharma_BI @AVIVA1950 Stanley Shaw, MD, PhD Realization by physicians that monitoring Patients @Home is a TIME SAVER – tech adopted

1 retweet

 

  1. Aviva Lev-Ari‏ @AVIVA1950 May 2

 

#WMIF17 @pharma_BI, @AVIVA1950, Increase Research at Eli Lilly CEO, medicine will bring value, can’t apologies for drug failure, best time

1 retweet

  1. Aviva Lev-Ari‏ @AVIVA1950 May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Offset AD prevent vs delay age of onsett is desirable, Pharma spend $70Billion on R&D, most is D NIH is R

1 retweet

Aviva Lev-Ari‏ @AVIVA1950  May 1

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, M… https://pharmaceuticalintelligence.com/2017/05/01/highlights-of-live-day-1-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

retweet

4

Liked

14

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

1 retweet 1 like

 

Retweeted

1

Liked

1

 

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017… https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ …

 

More

https://lnkd.in/dwiwJc6 

 

Like

11

More

Merck eyes key cancer drug growth as others lose patent protection

1 retweet0 likes

 

Retweet

1

 

 

Empowering students today to create the world of tomorrow

 

 

 

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

 

 

 

Highlights – LIVE Day 2: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

 

 

Highlights – LIVE Day 2: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017… https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states …

 

 

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

 

More

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017… https://pharmaceuticalintelligence.com/2017/05/01/highlights-of-live-day-1-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states …

 

  1. World Forum Retweeted your reply

 

8h8 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Disruptive Dozen 1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

9 other Retweets

AI Newsletter liked your reply

 

8h8 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Disruptive Dozen 2. Harnessing Big Data and Deep Learning for Clinical Decision Support

  1. Sek Kathiresan MD‏ @skathire10h10 hours ago

More

Sek Kathiresan MD Retweeted Aviva Lev-Ari

If competition/judging is ‘fair’ process, how is ‘20% taking up 50%’ a problem?

Sek Kathiresan MD added,

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons 20% investigators take up 50% of the grants squeezing out the bandwidth need younger generation

3 replies0 retweets2 likes

Reply

3

Retweet

Like

2

Sek Kathiresan MD liked your reply

10h10 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons 20% investigators take up 50% of the grants squeezing out the bandwidth need younger generation

Gabriel M Santibañez liked your reply

 

11h11 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Campbell Rogers, MD Imaging Efficiency free cost Plaque composition Coronary CT flow implication of stenosis

Intrepid Bio Retweeted your reply

 

12h12 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Aarif Khakoo, MD Amgen 1,500,000 stroke Genetics will bring the breakthrough to atherosclerosis

Bryan Yee Retweeted your reply

 

23h23 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Scott Wasserman, Amgen, AI will become part of Clinical Trial Design for investigational therapies and others

 

Bryan Yee and Gabriel M Santibañez liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Scott Wasserman, Amgen, AI will become part of Clinical Trial Design for investigational therapies and others

Gabriel M Santibañez Retweeted your Retweet

 

May 2

Eric TopolVerified account @EricTopol

A gluten-free diet may not be without hazard http://www.bmj.com/content/357/bmj.j1892 … potential of reduced grain intake & cardiovascular risk @bmj_latest #OA

Gabriel M Santibañez liked your Retweet

 

May 2

RISD @risd

‘Creativity is highly valued in all industries’ @virgilabloh #VirgilxRISD

 

Gabriel M Santibañez and 6 others followed you

 

May 2

World Forum Retweeted your Tweet

 

May 2

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Highlights – LIVE Day 2: World Medical Innovation Forum – https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

9 other Retweets

 

MB Caschetta and Michele Carbone liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Sean Harper, MD, Amgen Sean Harper, MD Investors:to Biotech – works on Oncology and on Orphan drugs

Michele Carbone liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Sean Harper, MD, Amgen in CVD complex traits phynotype more determinative then genotyping vs Oncology,

Pearl Freier liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@Pharma_BI @AVIVA1950 #WMIF17 Benjamin Scirica, FDA requires PRAGMATIC TRIAL DESIGN, IDENTIFY DIFFERENT POPULATION FOR EXISTING DRUGS,

Nicole Volpe Miller liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Omar Ishrak, PhD CEO, Medtronic Innovations are the essence of Medical Devices development as mission in technology

World Forum Retweeted your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Marc Semigran Myokardia Preclinical trials for early insights for Younger patient with cardiomiopaty and older patient

9 other Retweets

World Forum Retweeted your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Omar Ishrak, CEO, Medtronic Training Challenge Surgical Robotic patient comfort of minimal invasive therapy, cost lower

9 other Retweets

 

Shira Rubinoff and Mike Newkirk followed you

 

May 1

BrackenData liked your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 @AVIVA1950 Medical Devices – Prevention methods, Big data , AI, Heart Failure a role for Government like “CVD Moonshot”

BrackenData liked your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Lewis Sandy, MD UnitedHealth 30% of care cost is WASTE, eliminate!! Collaborations Pharma Devices: Data Analytics KEY

Gabriel M Santibañez liked your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Ronald Tompkins, MD: Regulatory FDA/Bureaucracy needs be non-adversarial relations with Hospitals or Academia or industry

Smart Medicine Retweeted your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 @AVIVA1950 Medical Devices – Prevention methods, Big data , AI, Heart Failure a role for Government like “CVD Moonshot”

 

Read Full Post »


e-Proceedings for Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

Curator and Reporter: Aviva Lev-Ari, PhD, RN

 

https://worldmedicalinnovation.org/agenda/

 

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017  BOSTON, MA • UNITED STATES

https://pharmaceuticalintelligence.com/2017/05/01/highlights-of-live-day-1-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma-%E2%80%A2-united-states/

Highlights – LIVE Day 2: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma-%E2%80%A2-united-states/

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma-%E2%80%A2-united-states/

Read Full Post »


Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017  BOSTON, MA • UNITED STATES

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover the event in

REAL TIME

Aviva Lev-Ari, PhD, RN will be streaming live from the floor of the Westin Hotel in Boston on May 1-3, 2017

@pharma_BI

@AVIVA1950

#WMIF17

Forthcoming SEVEN e-Books in 2017 AND Eight e-Books on Amazon.com

https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/

Biggest Voices in Cardiovascular Care

2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston

https://worldmedicalinnovation.org/agenda/

Wednesday, May 3, 2017

 

7:00 am – 7:30 am
Lilly Foyer
7:30 am – 7:55 am
Boston Scientific Ballroom
1:1 Fireside Chat: Robert Califf, MD, Commissioner (former), Food and Drug Administration
  • Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women’s Hospital
  • Hersey Professor of the Theory and Practice of Medicine, Soma Weiss, MD Distinguished Chair in Medicine, Harvard Medical School
  1. What is the state of play and the future of CVD
  2. Why Drugs are behind vs Devices
  3. Precision Medicine in CVD
  4. Nutraceuticals – more regulations??
  5. Insights that surprised you at FDA
  6. Redesign the FDA – Areas?
  7. Patient participacition post approval
Robert Califf, MD – Now at Duck
  • Commissioner (former), Food and Drug Administration
  1. CVD – drugs vs Devices
  2. Drugs are less exciting while devices are booming
  3. Effective therapies of generic drugs is remarkable
  4. Reimbursement system is messed up
  5. DIfferent drugs have equal effects and ROI is not there, Pharma are pursuing different areas
  6. Checkpoints drugs in Oncology has no analogy in CVD
  7. Enrollment in Clinical Trials: In oncology, patients flock to Trials – that is not the case with CVD Trials
  8. Precision Medicine is over inflated, it is demonstrated in Oncology, “in CVD, I wish to hear from you”
  9. System Biology and Drugs
  10. FDA – one drug is a success for several attempts, several is large
  11. FDA is not interested in the Mechanism, they are interested in identidying the population, demonstrate safety and efficacy no adverse events
  12. Investment in Devices looks better vs CVD Drugs, Biologics are different
  13. Food supplement for Prostate, some are harmful – Law forbid regulation of Nurtaceuticals not good for public health
  14. Academic centers: Duke and Partners are far advanced in HC landscape
  15. FDA works with CMS – demonstration of Value in Drugs – Pragmatic randomized Trials
  16. Total cost, better spent
  17. FDA is a Science-based Organization – tremendous people, amazing work – learned the regulation over time
  18. Political Corporation have same status like individual for First Amendment
  19. Regulate Cosmetics and Nurtaceuticals
  20. Ecosystem: Products, Patient Advocacy Groups and Regulators — better alignment
  21. Cooperation and interaction among agencies: NIH, FDA
  22. Speeding the process if Patients are involved earlier – Pragmatic study design
  23. CVD – reassurance the patient
7:55 am – 8:45 am
Boston Scientific Ballroom
Innovation in Translational Trials

CV/metabolic disorders comprise aggregates of many niche diseases that may be targeted with therapies against specific molecular alterations, yet the final potential markets are much larger. This model creates challenges for both drug development and patient care with implications for initial indication selection and design and execution of clinical trials – from first-in-human through post marketing studies.

 

  • Director, Translational Research Center, Massachusetts General Hospital
  • Professor of Medicine Harvard Medical School
  1. CVD Success stories NOT by Cardiologists
  2. Metabolic Drugs Clinical Trials: Outcome Trials – 4% each trial is $2Billion thousand of Patients
  3. Trial design
  4. Technologies
  5. Quality control in Clinical Trial in Russia, Gorgie – no metabolites in blood
  6. Biomarkers Predictor of responses
  • SVP, Global Head of Regenerative Medicine Unit, Head of Scientific Affairs, Japan, Takeda
  1. Stem Cells Skin cells or blood cells and converted to other cells
  2. development of Cell-based therapy for Cardiac myocytes: propiatory method to purify myocytes
  3. In Japan, Cardiac transplant in very small cases – Alternative for Heart Transplant for HF – development of gene therapy and stem cell converted to myocytes
  4. Govenrment initiative to develop regenerative medicine, procedure can be improved,
  5. approval for EF improval – conditional Approval given by Government on 100 patients
  6. Severe HF — cell therapy and procedure is consider
  7. Osaka University, cell transplantatio – in Acadedmic Center
  8. If efficacy and safety — continuous improvement – inject the cell be applied to more patient beyond CVD applications
  9. Post approval registry, call patient back every few month, HF continuos Monitoring
  • CMO, Verily
  1. Tools to make the Patient the center of the Trial and engaged
  2. Information arrives in Real Time with Analytics – value derived from Dashboard design
  3. Multidimensional Data
  4. Definition of Disease – not as a point once a year but continual
  5. Real Time monitoring, deep IT design, each Patient has own Portal, monitoring takes major resources, Large Informatics companies, screen ECG of huge populations
  6. FDA interested in NEW tools, data that comes from individual
  7. Biomarkers: Biosignals broader, connection Genomics and physiology – Neurlology
  8. CVD – BP druds and QT prolongation
  9. User-centric Design – Patient-center, data infrastructure for MDs
  • SVP, Global CMO, Novo Nordisk
  1. 2016 – three drug studies CVD and DM – Insulin: (1) Post market on Safety, (2) Preapproval assessement (3) Insulin study assess data without compromising the continuation of the study (CVRT)
  2. Engaging Patients and Investigators – Global Trials varies by Regions – Global Experts, Local Experts and RN as Coordinators — worked very well
  3. CVD Outcome Trials – engaging patients
  4. Intermediate Analysis: conduct and protect the Intermediate results no disclosure till Trial is completed
  5. Identify the right site id a challenge
  6. Multiple pathway related to CVD – Biomarkers difficult to find as insightful
  7. In Israel data integrity is the highest
  8. Innovative Medical Initiative – Novo, Lilly, Sanofi — DM data comparison
  • SVP & CSO, PAREXEL International – CRO
  1. Adaptive Trials vs Traditional Cardio (no windows) – intermediate evaluation
  2. Adaptive Trials: Flexibility 50% of Phase III Fails – Adaptive design offer more values
  3. OMICS revolution – innovative revolution
  4. Umbrella Design: different treatment for single indication
  5. Platform design – infrastructure design is inefficient vs Platform: Number of Drugs Several indications
  6. Interaction with FDA: They are open to Adaptive design wiht Power, survival rate window adaptive,
  7. Tufts data and PAREXEL: Adoption 30% of new design for Phase III: maintain blindness
  8. Data Surveillence during the Trial administration – look at data cycle time, monitor margins during the study Red flags identified before end of study
  9. Biomarkers in Early Translational Research – down stream processes to identify and validate
8:45 am – 9:15 am
Boston Scientific Ballroom
1:1 Fireside Chat: Michael Mahoney, CEO, Boston Scientific

Edward Lawrence, Board of Directors, Partners

Moderator: Meg Tirrell – Biotech, Pharma
  • Reporter, CNBC
Michael Mahoney ex-GE Medical HealthCare IT and J&J Diagnostics
  • CEO, Boston Scientific

Geography – Global vs 10 years ago US focus

Pipeline strategy – Diversified: Neurology, CVD, Endoscopy – innovation cycle very strong

  • Symatec – valve company – M&A – strengthen Strategy on TAVR
  • AF product
  • Deeper Stimulation for Parkinson
  • Mitral Valve Strategy: Venture bets with VC for repair and replacement
  • TAVR – volunteer recall back in Europe – P&A – fully deployed valve synergies with Symatec
  • Digital tool
  • GHX – B to B Healthcare Exchange – automate procurement, innovate the portfolio – supply chain cost reduction
  • 30 VC investment – microelectronics, AD Neuro-modulation, Obesity, Immunology
  • Sensors – prediction of HF – two devices: diagnostics-side to reduce hospital readmission – GO HOME with Alert system to avoid ER, diagnostics
  • Cnsolidation: growing very well: Drive Category leadership – Hospitals want to deal with three suppllier.
  • Partner of Choice for Partners
  • Acquisitions: Early stage and more mature
  • Challenges in Emerging Markets:
  1. Brazil – different that China or India
  2. China – more regulation for approval
  3. India – price very low – not to offer more expensive stents
  • Cyber security – Investment in this domain to secure data – not a market reaction to this issue
  • Reimbursement: Clinical path to get Approved – Upfront effort to align approval with Reimburement
  • FDA responsive to 2nd time improvement Clinical trial designed
  • Microelectronics new direction: Endoscopy GI Pulmonary,
  • SPINAL CORD STIMULATION: GU, GI (Crohn), Neuromodulation: Depression, Pain, Parkinson

 

9:15 am – 10:05 am
Boston Scientific Ballroom
New Targets in Coronary Artery Disease

Cardiovascular trials have a proud history of providing some of the most robust data in evidence-based medicine. However the growing size and complexity of these trials imperils their future. This panel will discuss the design and implementation of clinical studies globally, considering strategies for patient access, leveraging electronic health records and mobile device data, personalized medicine, regulatory implications, cost containment and management of relationships with global service providers.

  • Director, Center for Genomic Medicine, Massachusetts General Hospital
  • Associate Professor of Medicine, Harvard Medical School
  1. expose new pathways: Biology is most important, BP, High polygenic risk identification of patients for early treatment
  • VP Research, Cardiometabolic Disorders Therapeutic Area Head, Site Head Amgen San Francisco, Amgen
  1. 1,500,000 stroke
  2. CVD and atherosclerosis – is a complex disease
  3. at Amgen – Genetics will bring the breakthrough to atherosclerosis
  4. Cost is related to FAIL less – target selection is cardinal
  5. Phynotyping and genotyping for targeting the Patient that will benefit the most
Clive Meanwell, MD, PhD – Oncologist
  • CEO, The Medicines Company
  1. Orphan drugs for Genetic targets vs Opportunities of the prevalent diseases of the Heart
  2. Big Pharma are in CVD, do not discourage, CVD major cause of death
  3. Phase III needs different questions and more Phase IV needed
  4. Biomarkers:
  • Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital
  • Eugene Braunwald Professor of Medicine, Harvard Medical School
  1. Residual Real Risk: Inflammatory response, triglycerides innovations in LDLc reduction – Class of PSCK9
  2. Know biology, follow biology
  3. Science is endangered in WashDC
  • EVP, CMO, HeartFlow
  1. Clinical burden remains: Which patient will benefit?
  2. Value for Patient
  3. No investment in Coronary disease – Devices investment in this space, setbacks in bioabsorbable stents
  4. goal is holistic for economic value of the outcome of the trials
  5. Imaging Efficiency: Plaque composition, Coronary CT, flow implication of stenosis
  • CMO, Kowa Pharmaceuticals
  1. Is triglycerides the right focus
  2. Macrophage activation to prevent pathways and prevent resistance
  3. chronic HIV- pathophysiology – immune activation
  4. Pragmatic Clinical Trial Design: Novel Targets, preclinical must be faster, collaboration of Academia and Industry
10:05 am – 10:25 am
Lilly Foyer
10:25 am – 10:55 am
Boston Scientific Ballroom
1:1 Fireside Chat: Gary Gibbons, MD, NHLBI
  • President, Brigham Health
  • Professor of Medicine, Harvard Medical School
  1. What innovative projects at NHLBI
  2. Young Investigators
  3. Large Cohort studies: Framingham Study, 1958 – CVD Risk for: Policy: Lowering BP and Cholesterol
  4. CVD hot areas
  5. Value-based Care
Gary Gibbons, MD – Public Service, appointed by NIH Director, not by the President
  • Director, NHLBI
  1. Enabling other the pursuit of Science for Public Good
  2. Ecosystem – the Government arm –
  3. ROI – funds Projects
  4. KI – New Program – funding PIs – investigators initiatives – Next generation of Scholars
  5. 50% of KI converts to ROI
  6. Reduction in CVD is an ROI in research in CVD Biology and Drug development and Devices
  7. 2018 NIH Funding – last two years increase in budget, cuts may or may not occur
  8. Opportunity to reinvent Longitudinal Cohort Studies with insertion of Genomics sequencing – 7,000 Whole Genome – target 100,000
  9. Concepts of Data Commons – Sharing ONE resource for distributed Analytics: Reusability, interoperability, API
  10. CVD – portfolio to include Minority Population disease prevalent
  11. Translation of Science, concept mechanism
  12. Epigenomics and Patho-biology DB and changes over time -a rare resource
  13. Science is to be done for the Public Good, commonwealth of the entire nation – Accessibility of Genome Data after the National goal of sequencing the Genome
  14. 20% investigators take up 50% of the grants and squeeze out the younger generation
  15. Pragmatic optimist in this position, scientists innovate for Patients

 

10:55 am – 11:45 am
Boston Scientific Ballroom
The Skinny on Fat: Therapeutic Opportunities

Explore the evolving role of adipose tissue as an active endocrine organ and discuss the possibilities to discover novel signaling pathways relevant to cardiovascular health and viable druggable targets.

  • SVP and US Medical Leader, Eli Lilly and Company
  1. Obesity and DM2 – direct (Heart Disease Arthritis) and indirect cost (quality of life and productivity)
  2. What is most exciting
  3. What is the challenges
  4. Best ideas
  5. NASH
  6. Microbiome
  7. Food Science
  • SVP and CSO, CVMET, Pfizer, Cambridge
  1. Cardiometabolic in same department with Neurodegenerative Disease – affected by metabolic state
  2. Behavior modification does not work – 1:1 care is too expensive
  3. therapeutics needed for obesity
  4. Which drugs will be translatable
  5. NASH – most die with Heart disease – if NASH treated no death??
  • Global VP, Cardiovascular, Renal and Metabolism AstraZeneca
  1. Renal condition CKD
  2. CVD
  3. comorbidity
  4. Drug perspective: White fat in not inert, signalling
  5. combination of drug
  6. compounds that have impact on CV system
  7. Three Barriers: (1) Science, (2) access to medicines (3) holistic approach: Nephrology needs to use DM drugs, Cardiologist other drugs than cardiac drugs
  8. NASH – it is a REAL disease, impact on Patient
Thomas Hughes, PhD – ex-Novartis
  • CEO, Zafgen
  1. Inhibiting enzyme in obisity for weight reduction
  2. Inflammation burden, lipid, thrombotic events
  3. NASH
  4. Fat and glucose metabolism – integrated physiologic view
  5. Cardiovascular Outcomes: lack of harm vs showing benefit caused by emerging therapies
  6. Food and obesity
  • Director, Obesity, Metabolism & Nutrition Institute, Massachusetts General Hospital
  • Associate Professor, Harvard Medical School
  1. MGH-GI, Bariatric Surgery, effect on comorbidity Vascular Pressure –>> Hypertrophy, conduction and Arryhythmia
  2. Obesity in 6 Countries not only in US, Urban and Rural
  3. CVD occurs in Asia in absence of Obesity
  4. Bariatric surgery is not a public solution – it affects the gut different that drugs do
  5. what get a person to obesity and waht maintain the obesity
  6. complications of obisity – abnormal target of stores
  7. move from the ideas of calories consumption vs Brain function
  8. Develop drug against the complications vs against the obesity itself: Science of Obesity not understood,
  9. Voluntary obesity vs life style – stigma against obesity, heterogenous disease
  10. Microbiome – effect size is small master regulator are interactive Pro-biotics needs to be invented

Bruce Spiegelman, PhD

  • Stanley J. Korsmeyer Professor of Cell Biology and Medicine, Dana Farber Cancer Institute, Harvard Medical School
  1. Molecular development of fat molecule and in exercise impart on energy expansion,
  2. Capture the molecules that participate in exercise to be given to bedridden patients
  3. Obesity is a disease of energy imbalance – Food Intake and Energy expenditure – BEIGE FAT cells that expend energy
  4. Molecular involvement: Exercise causes neurogenesis: ALS, Parkinson, AD
  5. Exercise affect, Heart, Brain and cognition
  6. Science had budget challenge, Biotech, Pharma: CVD Outcomes studies
  7. R&D has challenges to get traction
  8. Microbiome – natural context  provide modest benefit, some effects
11:45 am – 12:45 pm
Boston Scientific Ballroom
Disruptive Dozen: 12 Technologies that will reinvent Cardiovascular Care
  • Chief of Cardiovascular Medicine, Brigham and Women’s Hospital
  • Associate Professor of Medicine, Harvard Medical School
  • Chief, Cardiology Division, Massachusetts General Hospital
  • Professor of Medicine, Harvard Medical School

12. Aging and Heart Disease: Can we reverse the process?

11.Nanotechnologies for Cardiac Diagnosis and Treatment

10. Breaking the Code: Diagnosis and Therapeutic Potential of RNA

9. Expanding the Pool of Organs for Transplant

8. Finding Cancer therapies without Cardiotoxicity

7. Less is more: Minimalist Mitral Valve Repair

6. Understanding Why exercise works for Just about every thing

5. Power Play: The Future of Implantable Cardiac Devices

4. Adopting the Orphan of Heart Disease

3. Targeting Inflammation in cardiovascular Disease

2. Harnessing Big Data and Deep Learning for Clinical Decision Support

  1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

 

1:00 pm
Lilly Foyer

Read Full Post »

Older Posts »